Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $138.9 million.

  • Monte Rosa Therapeutics' Net Cash Flow rose 72834.82% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 2377.07%. This contributed to the annual value of $96.4 million for FY2024, which is 3303.17% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Net Cash Flow is $138.9 million, which was up 72834.82% from -$9.0 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Net Cash Flow registered a high of $138.9 million during Q3 2025, and its lowest value of -$145.7 million during Q1 2025.
  • Moreover, its 3-year median value for Net Cash Flow was $9.1 million (2024), whereas its average is $13.9 million.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Net Cash Flow crashed by 81659.05% in 2024, and later skyrocketed by 72834.82% in 2025.
  • Monte Rosa Therapeutics' Net Cash Flow (Quarter) stood at $69.1 million in 2023, then soared by 42.73% to $98.6 million in 2024, then soared by 40.84% to $138.9 million in 2025.
  • Its Net Cash Flow was $138.9 million in Q3 2025, compared to -$9.0 million in Q2 2025 and -$145.7 million in Q1 2025.